S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
Log in

NASDAQ:STIMNeuronetics Stock Price, Forecast & News

$3.01
+0.30 (+11.07 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.86
Now: $3.01
$3.27
50-Day Range
$1.82
MA: $2.32
$3.30
52-Week Range
$1.25
Now: $3.01
$12.20
Volume772,026 shs
Average Volume582,451 shs
Market Capitalization$56.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Read More
Neuronetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STIM
CUSIPN/A
CIKN/A
Phone610-640-4202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$62.66 million
Book Value$2.57 per share

Profitability

Net Income$-29,040,000.00

Miscellaneous

Employees191
Market Cap$56.37 million
Next Earnings Date8/4/2020 (Confirmed)
OptionableNot Optionable
$3.01
+0.30 (+11.07 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neuronetics (NASDAQ:STIM) Frequently Asked Questions

How has Neuronetics' stock been impacted by COVID-19 (Coronavirus)?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STIM shares have increased by 45.4% and is now trading at $3.01.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Neuronetics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neuronetics
.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Neuronetics
.

How can I listen to Neuronetics' earnings call?

Neuronetics will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Neuronetics' earnings last quarter?

Neuronetics Inc (NASDAQ:STIM) released its earnings results on Tuesday, May, 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.13. The company earned $11.48 million during the quarter. Neuronetics had a negative return on equity of 68.77% and a negative net margin of 55.58%.
View Neuronetics' earnings history
.

What price target have analysts set for STIM?

4 Wall Street analysts have issued twelve-month target prices for Neuronetics' shares. Their forecasts range from $4.00 to $6.00. On average, they expect Neuronetics' share price to reach $5.33 in the next twelve months. This suggests a possible upside of 77.2% from the stock's current price.
View analysts' price targets for Neuronetics
.

Has Neuronetics been receiving favorable news coverage?

Headlines about STIM stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuronetics earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
View the latest news about Neuronetics
.

Are investors shorting Neuronetics?

Neuronetics saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 269,900 shares, a decline of 18.2% from the June 30th total of 329,900 shares. Based on an average daily trading volume, of 968,100 shares, the short-interest ratio is presently 0.3 days. Approximately 2.7% of the shares of the stock are sold short.
View Neuronetics' Current Options Chain
.

Who are some of Neuronetics' key competitors?

What other stocks do shareholders of Neuronetics own?

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:
  • Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
  • Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)
  • Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
  • Ms. Cassie Hallberg, VP of Marketing
  • Mr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42)

When did Neuronetics IPO?

(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $3.01.

How big of a company is Neuronetics?

Neuronetics has a market capitalization of $56.37 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe.

What is Neuronetics' official website?

The official website for Neuronetics is www.neurostar.com.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.